Anti-TATA binding protein TBP antibody (ab70009)

Overview

  • Product nameAnti-TATA binding protein TBP antibodySee all TATA binding protein TBP primary antibodies ...
  • Description
    Rabbit polyclonal to TATA binding protein TBP
  • Tested applicationsWB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide (Human) from an internal region

  • Positive control
    • 293 cell extract

Properties

Applications

Our Abpromise guarantee covers the use of ab70009 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 38 kDa (predicted molecular weight: 38 kDa).
ELISA 1/40000.

Target

  • FunctionGeneral transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID. Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex (PIC), playing a role in the activation of eukaryotic genes transcribed by RNA polymerase II. Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (preinitiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with the rDNA promoter. SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA.
  • Tissue specificityWidely expressed, with levels highest in the testis and ovary.
  • Involvement in diseaseDefects in TBP are the cause of spinocerebellar ataxia type 17 (SCA17) [MIM:607136]. Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA17 is an autosomal dominant cerebellar ataxia (ADCA) characterized by widespread cerebral and cerebellar atrophy, dementia and extrapyramidal signs. The molecular defect in SCA17 is the expansion of a CAG repeat in the coding region of TBP. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.
  • Sequence similaritiesBelongs to the TBP family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • GTF2D antibody
    • GTF2D1 antibody
    • HDL4 antibody
    • MGC117320 antibody
    • MGC126054 antibody
    • MGC126055 antibody
    • SCA17 antibody
    • TATA binding factor antibody
    • TATA box factor antibody
    • TATA sequence binding protein antibody
    • TATA sequence-binding protein antibody
    • TATA-binding factor antibody
    • TATA-box binding protein N-terminal domain antibody
    • TATA-box factor antibody
    • TATA-box-binding protein antibody
    • TBP antibody
    • TBP_HUMAN antibody
    • TFIID antibody
    • Transcription initiation factor TFIID TBP subunit antibody
    see all

Anti-TATA binding protein TBP antibody images

  • All lanes : Anti-TATA binding protein TBP antibody (ab70009)

    Lane 1 : 293 cells
    Lane 2 : 293 cells with blocking peptide


    Predicted band size : 38 kDa

References for Anti-TATA binding protein TBP antibody (ab70009)

This product has been referenced in:
  • Ma J  et al. Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 78:830-7 (2010). WB ; Mouse . Read more (PubMed: 19995896) »

See 1 Publication for this product

Product Wall

Thank you for contacting us. The predicted band size for this protein is 38KDa, as shown in the bottom image. However, the bands sizes can differ from the predicted and appear at different molecular weights, due to different possible factors, as post-t...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"